Pregabalin in the treatment of chronic pain: An overview

Clinical Drug Investigation

Volumn 29, Issue 3, 2009, Pages 203-213

  Chiechio, S ^a   Zammataro, M ^a   Caraci, F ^a   Rampello, L ^a   Copani, A ^a   Sabato, A F ^b   Nicoletti, Ferdinando ^c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTACID AGENT; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CANNABINOID; CLOMIPRAMINE; DULOXETINE; GABAPENTIN; IBUPROFEN; IMIPRAMINE; LAMOTRIGINE; LIDOCAINE; METHADONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXCARBAZEPINE; PLACEBO; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VOLTAGE GATED CALCIUM CHANNEL;

ALPHA CHAIN; ANALGESIA; ANXIETY; BINDING AFFINITY; CANCER PAIN; CERVICOBRACHIAL NEURALGIA; CHRONIC PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; EUROPE; HUMAN; NEUROPATHIC PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; NONHUMAN; PHARMACEUTICAL CARE; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN TARGETING; QUALITY OF LIFE INDEX; RADICULOPATHY; RESTLESS LEGS SYNDROME; REVIEW; SENSORY NERVE CELL; SIDE EFFECT; SINGLE DRUG DOSE; SLEEP DISORDER; SPINAL CORD DORSAL HORN; SPINE INJURY; SYNAPTIC TRANSMISSION; TOOTH PAIN; WATER RETENTION; WESTERN HEMISPHERE; XEROSTOMIA;

AMINES; ANALGESICS, NON-NARCOTIC; ANIMALS; CALCIUM CHANNELS; CHRONIC DISEASE; CYCLOHEXANECARBOXYLIC ACIDS; GAMMA-AMINOBUTYRIC ACID; GUIDELINES AS TOPIC; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 61349198712     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929030-00006     Document Type: Review

References (104)

1. Woolf CJ, Shortland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992 Jan 2; 355 (6355): 75-8
2. Doubell TP, Mannion RJ, Woolf CJ. Intact sciatic myelinated primary afferent terminals collaterally sprout in the adult rat dorsal horn following section of a neighbouring peripheral nerve. J Comp Neurol 1997 Mar 31; 380 (1): 95-104
3. Caterina MJ, Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 2001; 24: 487-517
4. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997 Oct 23; 389 (6653): 816-24
5. Davis JB, Gray J, Gunthorpe MJ, et al. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 2000 May 11; 405 (6783): 183-7
6. Caterina MJ, Leffler A, Malmberg AB, et al. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 2000 Apr 14; 288 (5464): 306-13
7. Tominaga M, Caterina MJ, Malmberg AB, et al. The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998 Sep; 21 (3): 531-43
8. Jordt SE, Tominaga M, Julius D. Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci U S A 2000 Jul 5; 97 (14): 8134-9
9. Hwang SW, Cho H, Kwak J, et al. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 2000 May 23; 97 (11): 6155-60
10. Ahern GP, Brooks IM, Miyares RL, et al. Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. J Neurosci 2005 May 25; 25 (21): 5109-16
11. Zygmunt PM, Petersson J, Andersson DA, et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999 Jul 29; 400 (6743): 452-7
12. Bhave G, Zhu W, Wang H, et al. cAMP-dependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 2002 Aug 15; 35 (4): 721-31
13. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000 Dec 21-28; 408 (6815): 985-90
14. Bhave G, Hu HJ, Glauner KS, et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 2003 Oct 14; 100 (21): 12480-5
15. Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005 Dec 21; 24 (24): 4211-23
16. 2+ channels. Annu Rev Cell Dev Biol 2000; 16: 521-55
17. Black JA, Dib-Hajj S, McNabola K, et al. Spinal sensory neurons express multiple sodium channel alpha-subunit mRNAs. Brain Res Mol Brain Res 1996 Dec 31; 43 (1-2): 117-31
18. Rush AM, Brau ME, Elliott AA, et al. Electrophysiological properties of sodium current subtypes in small cells from adult rat dorsal root ganglia. J Physiol 1998 Sep 15; 511 (Pt 3): 771-89
19. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999 Jun; 2 (6): 541-8
20. Yoshimura M, Jessell T. Amino acid-mediated EPSPs at primary afferent synapses with substantia gelatinosa neurones in the rat spinal cord. J Physiol 1990 Nov; 430: 315-35
21. Randic M, Jiang MC, Cerne R. Long-term potentiation and long-term depression of primary afferent neuro-transmission in the rat spinal cord. J Neurosci 1993 Dec; 13 (12): 5228-41
22. Gerber G, Zhong J, Youn D, et al. Group II and group III metabotropic glutamate receptor agonists depress synaptic transmission in the rat spinal cord dorsal horn. Neuroscience 2000; 100 (2): 393-406
23. Gerber G, Youn DH, Hsu CH, et al. Spinal dorsal horn synaptic plasticity: involvement of group I metabotropic glutamate receptors. Prog Brain Res 2000; 129: 115-34
24. Catterall WA, Perez-Reyes E, Snutch TP, et al. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005 Dec; 57 (4): 411-25
25. Hofmann F, Biel M, Flockerzi V. Molecular basis for Ca2+ channel diversity. Annu Rev Neurosci 1994; 17: 399-418
26. Ertel EA, Campbell KP, Harpold MM, et al. Nomenclature of voltage-gated calcium channels. Neuron 2000 Mar; 25 (3): 533-5
27. Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994 Jun; 269 (3): 1117-23
28. Malmberg AB, Yaksh TL. Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N- and P-type channels inhibits formalin-induced nociception. J Neurosci 1994 Aug; 14 (8): 4882-90
29. Bowersox SS, Gadbois T, Singh T, et al. Selective N-type neuronal voltage-sensitive calcium channel blocker, SNX-111, produces spinal antinociception in rat models of acute, persistent and neuropathic pain. J Pharmacol Exp Ther 1996 Dec; 279 (3): 1243-9
30. Neugebauer V, Vanegas H, Nebe J, et al. Effects of N- and L-type calcium channel antagonists on the responses of nociceptive spinal cord neurons to mechanical stimulation of the normal and the inflamed knee joint. J Neurophysiol 1996 Dec; 76 (6): 3740-9
31. Diaz A, Dickenson AH. Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation. Pain 1997 Jan; 69 (1-2): 93-100
32. Sluka KA. Blockade of N- and P/Q-type calcium channels reduces the secondary heat hyperalgesia induced by acute inflammation. J Pharmacol Exp Ther 1998 Oct; 287 (1): 232-7
33. Saegusa H, Kurihara T, Zong S, et al. Suppression of inflammatory and neuropathic pain symptoms in mice lacking the N-type Ca2+ channel. EMBO J 2001 May 15; 20 (10): 2349-56
34. Jay SD, Sharp AH, Kahl SD, et al. Structural characterization of the dihydropyridine-sensitive calcium channel alpha 2-subunit and the associated delta peptides. J Biol Chem 1991 Feb 15; 266 (5): 3287-93
35. Marais E, Klugbauer N, Hofmann F. Calcium channel alpha(2)delta subunits-structure and gabapentin binding. Mol Pharmacol 2001 May; 59 (5): 1243-8
36. Brown JP, Gee NS. Cloning and deletion mutagenesis of the alpha2 delta calcium channel subunit from porcine cerebral cortex: expression of a soluble form of the protein that retains [3H]gabapentin binding activity. J Biol Chem 1998 Sep 25; 273 (39): 25458-65
37. 2+ channel subunit from porcine brain: development of a radioligand binding assay for alpha 2 delta subunits using [3H]leucine. Anal Biochem 1998 Jan 15; 255 (2): 236-43
38. Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996 Mar 8; 271 (10): 5768-76
39. Hill DR, Suman-Chauhan N, Woodruff GN. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993 Feb 15; 244 (3): 303-9
40. Suman-Chauhan N, Webdale L, Hill DR, et al. Characterisation of [3H]gabapentin binding to a novel site in rat brain: homogenate binding studies. Eur J Pharmacol 1993 Feb 15; 244 (3): 293-301
41. Wang M, Offord J, Oxender DL, et al. Structural requirement of the calcium-channel subunit alpha2delta for gabapentin binding. Biochem J 1999 Sep 1; 342 (Pt 2): 313-20
42. Bian F, Li Z, Offord J, et al. Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-deltatype 1 genetically modified mice. Brain Res 2006 Feb 23; 1075 (1): 68-80
43. Li CY, Song YH, Higuera ES, et al. Spinal dorsal horn calcium channel alpha2delta-1 subunit upregulation contributes to peripheral nerve injury-induced tactile allodynia. J Neurosci 2004 Sep 29; 24 (39): 8494-9
44. Melrose HL, Kinloch RA, Cox PJ, et al. [3H] Pregabalin binding is increased in ipsilateral dorsal horn following chronic constriction injury. Neurosci Lett 2007 May 1; 417 (2): 187-92
45. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther 2002 Dec; 303 (3): 1199-205
46. Maneuf YP, Hughes J, McKnight AT. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudal trigeminal nucleus slices. Pain 2001 Aug; 93 (2): 191-6
47. Dooley DJ, Mieske CA, Borosky SA. Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 2000 Feb 18; 280 (2): 107-10
48. Fehrenbacher JC, Taylor CP, Vasko MR. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003 Sep; 105 (1-2): 133-41
49. Guay DR. Pregabalin in neuropathic pain: a more "pharmaceutically elegant" gabapentin? Am J Geriatr Pharmacother 2005 Dec; 3 (4): 274-87
50. Taylor CP. Emerging perspectives on the mechanism of action of gabapentin. Neurology 1994 Jun; 44 (6 Suppl. 5): S10-6; discussion S31-2
51. Zareba G. Pregabalin: a new agent for the treatment of neuropathic pain. Drugs Today (Barc) 2005 Aug; 41 (8): 509-16
52. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. Am J Health Syst Pharm 2007 Jul 15; 64 (14): 1475-82
53. Micheva KD, Taylor CP, Smith SJ. Pregabalin reduces the release of synaptic vesicles from cultured hippocampal neurons. Mol Pharmacol 2006 Aug; 70 (2): 467-76
54. Rosenmund C, Stevens CF. Definition of the readily releasable pool of vesicles at hippocampal synapses. Neuron 1996 Jun; 16 (6): 1197-207
55. Holz RW. Pharmacology meets vesicular trafficking at a central nervous system synapse: pregabalin effects on synaptic vesicle cycling in hippocampal neurons. Mol Pharmacol 2006 Aug; 70 (2): 444-6
56. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002 Nov-Dec; 18 (6): 350-4
57. Skyler JS. Diabetic complications: the importance of glucose control. Endocrinol Metab Clin North Am 1996 Jun; 25 (2): 243-54
58. Giardino I, Edelstein D, Brownlee M. Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity: a model for intracellular glycosylation in diabetes. J Clin Invest 1994 Jul; 94 (1): 110-7
59. Shinohara M, Thornalley PJ, Giardino I, et al. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 1998 Mar 1; 101 (5): 1142-7
60. Williamson JR, Chang K, Frangos M, et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes 1993 Jun; 42 (6): 801-13
61. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998 Jun; 47 (6): 859-66
62. Kolm-Litty V, Sauer U, Nerlich A, et al. High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J Clin Invest 1998 Jan 1; 101 (1): 160-9
63. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000 Oct 24; 97 (22): 12222-6
64. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004 Aug; 110 (3): 628-38
65. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004 Dec 14; 63 (11): 2104-10
66. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005 Apr; 6 (4): 253-60
67. Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005 Jun; 115 (3): 254-63
68. Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008 Feb; 12 (2): 203-13
69. Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004 May; 109 (1-2): 26-35
70. Owen RT. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today (Barc) 2007 Sep; 43 (9): 601-10
71. Bandelow B, Wedekind D, Leon T. Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention. Expert Rev Neurother 2007 Jul; 7 (7): 769-81
72. Gershon AA. Epidemiology and management of postherpetic neuralgia. Semin Dermatol 1996 Jun; 15 (2 Suppl. 1): 8-13
73. Volpi A, Gatti A, Serafini G, et al. Clinical and psychosocial correlates of acute pain in herpes zoster. J Clin Virol 2007 Apr; 38 (4): 275-9
74. Dworkin RH, Corbin AE, Young Jr JP, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003 Apr 22; 60 (8): 1274-83
75. Van Seventer R, Feister HA, Young Jr JP, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006 Feb; 22 (2): 375-84
76. Tarride JE, Gordon A, Vera-Llonch M, et al. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006 Nov; 28 (11): 1922-34
77. Baron R, Brunnmuller U, Brasser M, et al. Efficacy and safety of pregabalin in patients with diabetic peripheral neuropathy or postherpetic neuralgia: open-label, non-comparative, flexible-dose study. Eur J Pain 2008 Oct; 12 (7): 850-58
78. Siddall PJ, Taylor D, Cousins MJ. Pain associated with spinal cord injury. Curr Opin Neurol 1995 Dec; 8 (6): 447-50
79. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000 Jun 9; 288 (5472): 1765-9
80. Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006 Nov 28; 67 (10): 1792-800
81. Dahl JB, Mathiesen O, Moiniche S. 'Protective premedication': an option with gabapentin and related drugs? A review of gabapentin and pregabalin in the treatment of post-operative pain. Acta Anaesthesiol Scand 2004 Oct; 48 (9): 1130-6
82. Hill CM, Balkenohl M, Thomas DW, et al. Pregabalin in patients with postoperative dental pain. Eur J Pain 2001; 5 (2): 119-24
83. Reuben SS, Buvanendran A, Kroin JS, et al. The analgesic efficacy of celecoxib, pregabalin, and their combination for spinal fusion surgery. Anesth Analg 2006 Nov; 103 (5): 1271-7
84. Jokela R, Ahonen J, Tallgren M, et al. A randomized controlled trial of perioperative administration of pregabalin for pain after laparoscopic hysterectomy. Pain 2008 Jan; 134 (1-2): 106-12
85. Walters AS. Toward a better definition of the restless legs syndrome: the International Restless Legs Syndrome Study Group. Mov Disord 1995 Sep; 10 (5): 634-42
86. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005 Jun 13; 165 (11): 1286-92
87. Hening W, Allen RP, Tenzer P, et al. Restless legs syndrome: demographics, presentation, and differential diagnosis. Geriatrics 2007 Sep; 62 (9): 26-9
88. Kushida CA. Pramipexole for the treatment of restless legs syndrome. Expert Opin Pharmacother 2006 Mar; 7 (4): 441-51
89. Bogan RK. Ropinirole treatment for restless legs syndrome. Expert Opin Pharmacother 2008 Mar; 9 (4): 611-23
90. Sommer M, Bachmann CG, Liebetanz KM, et al. Pregabalin in restless legs syndrome with and without neuropathic pain. Acta Neurol Scand 2007 May; 115 (5): 347-50
91. McGeeney BE. Adjuvant agents in cancer pain. Clin J Pain 2008 May; 24 Suppl. 10: S14-20
92. Vondracek P, Oslejskova H, Kepak T, et al. Efficacy of pregabalin in neuropathic pain in paediatric oncological patients. Eur J Paediatr Neurol. Epub 2008 Sep 5
93. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl. 6: 13-8
94. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005 Mar 31; 352 (13): 1324-34
95. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 2007 Jan; 29 (1): 26-48
96. Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr Opin Anaesthesiol 2007 Oct; 20 (5): 456-72
97. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998 Dec 2; 280 (21): 1831-6
98. Gorson KC, Schott C, Herman R, et al. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry 1999 Feb; 66 (2): 251-2
99. Simpson D. Gabapentin and venlafaxine for the treatment of painful diabetic neuropathy. J Clin Neuromuscular Dis 2001; 3 (2): 53-62
100. Morello CM, Leckband SG, Stoner CP, et al. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999 Sep 13; 159 (16): 1931-7
101. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006 Nov; 13 (11): 1153-69
102. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007 Spring; 12 (1): 13-21
103. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006 Apr; 81 (4 Suppl.): S12-25
104. Finnerup NB, Otto M, McQuay HJ, et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain 2005 Dec 5; 118 (3): 289-305